retatrutide triple agonist gip glp-1 glucagon phase 2 obesity A review of an investigational drug retatrutide, a novel agent for the treatment of | European Journal of Clinical Pharmacology Retatrutide, a TRIPLE agonist (GLP1,
Pay in 4 interest-free payments of $6.04 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2



























